Showing results (191-200 of 259) with videos related to

Sort By:
Pageof 26
Molecular Cancer Research : MCR|April 22, 2020
Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15aTengteng Yu, Chenxing Du, Xiaoke Ma, et al.
Annals of Hematology|April 19, 2022
Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variantYi Wang, Tingyu Wang, Ying Yu, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 8, 2018
Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple MyelomaYan Xu, Shuhui Deng, Xuehan Mao, et al.
Clinical & Translational Immunology|January 30, 2020
Prominent immune signatures of T cells are specifically associated with indolent B-cell lymphoproliferative disorders and predict prognosisShuhua Yi, Yu Zhang, Wenjie Xiong, et al.
Oncotarget|March 5, 2016
Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemiaMarilisa Marinelli, Caterina Ilari, Yi Xia, et al.
JAMA Oncology|November 7, 2024
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical TrialChunrui Li, Keshu Zhou, Yongxian Hu, et al.
Frontiers in Immunology|May 26, 2023
Minimal residual disease status improved the response evaluation in patients with Waldenström's macroglobulinemiaWenjie Xiong, Zanzan Wang, Tingyu Wang, et al.
Nature Communications|June 27, 2026
Bispecific antibody engineered extracellular vesicles redirect T cells to prevent postoperative epidural fibrosisShanwei Ye, Qian Xu, Yong Xu, et al.
The Lancet. Haematology|January 8, 2019
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trialYuankai Shi, Hang Su, Yongping Song, et al.
Nature Communications|July 11, 2022
Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balanceJiliang Xia, Jingyu Zhang, Xuan Wu, et al.
Pageof 26